Showing results (21-30 of 63) with videos related to

Sort By:
Pageof 7
Cancer Chemotherapy and Pharmacology|February 15, 2021
Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancerFilipa Lynce, James T Williams, Meredith M Regan, et al.
Cancer Chemotherapy and Pharmacology|November 13, 2004
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neckMatthew M Cooney, Kou-Yi Tserng, Vinit Makar, et al.
Clinical Breast Cancer|December 26, 2018
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor GradeHeather A Jacene, Trisha Youn, Pamela J DiPiro, et al.
Annals of Surgical Oncology|June 1, 2017
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast CancerFaina Nakhlis, Meredith M Regan, Laura E Warren, et al.
Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.
Cancer Research|June 18, 2002
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancerAfshin Dowlati, Kelly Robertson, Matthew Cooney, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancerSonia Pernas, Jennifer L Guerriero, Sergey Naumenko, et al.
Breast Cancer Research and Treatment|August 21, 2021
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutationsJing Xu, Tanya E Keenan, Beth Overmoyer, et al.
Clinical Breast Cancer|October 22, 2019
Aggressive Subsets of Metastatic Triple Negative Breast CancerJasneet Singh, Sarah Asad, Yiqing Zhang, et al.
The Lancet. Oncology|February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trialCarlo Palmieri, Hannah Linden, Stephen N Birrell, et al.
Pageof 7